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Nowadays steroid manufacturing occupies a prominent place in the pharmaceutical
industry with an annual global market over $10 billion. The synthesis of steroidal
active pharmaceutical ingredients (APIs) such as sex hormones (estrogens, androgens,
and progestogens) and corticosteroids is currently performed by a combination of
microbiological and chemical processes. Several mycobacterial strains capable of
naturally metabolizing sterols (e.g., cholesterol, phytosterols) are used as biocatalysts to
transform phytosterols into steroidal intermediates (synthons), which are subsequently
used as key precursors to produce steroidal APIs in chemical processes. These
synthons can also be modified by other microbial strains capable of introducing
regio- and/or stereospecific modifications (functionalization) into steroidal molecules.
Most of the industrial microbial strains currently available have been improved
through traditional technologies based on physicochemical mutagenesis and selection
processes. Surprisingly, Synthetic Biology and Systems Biology approaches have hardly
been applied for this purpose. This review attempts to highlight the most relevant
research on Steroid Biotechnology carried out in last decades, focusing specially on
those works based on recombinant DNA technologies, as well as outlining trends
and future perspectives. In addition, the need to construct new microbial cell factories
(MCF) to design more robust and bio-sustainable bioprocesses with the ultimate aim of
producing steroids à la carte is discussed.
Keywords: steroid, pharmaceuticals, actinobacteria, microbial cell factory, metabolic engineering, systems
biology
INTRODUCTION
Steroids are a family of terpenoid lipids widely distributed in nature that present a relatively rigid
common structure named gonane formed by four fused alicyclic rings (Figure 1). The oxidation
state of the steroid nucleus rings and the presence of different attached functional groups determine
the particular biological properties of each steroidic molecule, i.e., its biological function (Lednicer,
2011). Steroidal compounds play important biological roles in different organisms, including cell
membrane stabilization and regulation of relevant cellular processes such as cell proliferation and
tissue differentiation. For instance, sterols having a hydroxyl group at C-3 and a side-chain of eight
or more carbon atoms at C-17 act as stabilizing agents in cell membranes in animals (cholesterol),
plants (phytosterols), yeasts and fungi (ergosterol), and certain bacteria (e.g., lanosterol) (Figure 1;
Pearson et al., 2003; Lamb et al., 2007; Nelson and Cox, 2012;Wei et al., 2016). Steroidal compounds
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are also relevant carbon and energy sources for different bacteria
(Galán et al., 2017a) and appear participate in various cellular
signaling mechanisms.
Steroid-based drugs present a broad range of therapeutic
applications and represent the highest marketed category of
pharmaceuticals after antibiotics with an annual production of
more than one million tons. According to Tong and Dong
(2009) the annual global market for steroid-containing products
exceeds $10 billion with about 300 steroid drugs approved to
date (Sedlaczek and Leland, 1988; Demain, 1992; Bureik and
Bernhardt, 2007; Donova, 2017). Nevertheless the recent Global
Steroids-Corticosteroid Market Research Report 2017 estimates
a market size of 3,840 million $ in 2016 and it will reach 4,680
million $ by 2021 (Reports and Market, India). First studies on
steroid synthesis took place in the early twentieth century and
were notably increased in the 1950s due to the discovery of the
pharmacological properties of progesterone and hydrocortisone.
Steroidal active pharmaceutical ingredients (APIs) have been
classically synthesized by chemical processes (Herráiz, 2017).
However, the potential of microbial steroid biotransformation
is known since several decades since its application offer a
number of advantages over chemical synthesis: (i) regio- and/or
stereospecific functionalization of molecules at positions not
always available for chemical agents, (ii) multiple consecutive
reactions carried out in a single operation step, (iii) more eco-
friendly processes (i.e., mild reaction conditions, aqueousmedia).
One of the first demonstrations of this potential was described
with the production of cortisone. Traditionally, cortisone was
synthesized from deoxycholic acid in a multi-step chemical
process (31 steps) characterized by low mass yields (0.16%)
and high economic costs (200 $/g, 1949). The incorporation of
a biotransformation step with Rhizopus arrhizus ATCC 11145
and Aspergillus niger ATCC 9142 markedly reduced the number
of required chemical steps (11 steps) and production costs
(1$/g, 1979) of the industrial process (Carballeira et al., 2009).
Similarly, other chemical steps have been replaced by microbial
bioconversions in steroid synthesis processes in the last decades,
leading to more competitive and robust industrial processes. For
example, the steroid hormone testosterone (TS) is chemically
synthesized from the steroidal intermediate 4-androstene-3,17-
dione (AD), which is previously obtained from natural sterols
by microbial biotransformation (Fernández-Cabezón et al.,
2017a).
In this context, this review aims to compile the most relevant
microbial bioprocesses of synthesis and/or functionalization of
steroidal compounds described to date, focusing mainly on
those designed in the light of the new metabolic engineering
approaches. These bioprocesses, conventionally classified within
the scope of White or Industrial Biotechnology, have been
designed primarily by traditional approaches based on the
isolation of microorganisms that produce a molecule of interest
or that biocatalyze a particular process and their subsequent
improvement through tedious processes of physical or chemical
mutagenesis and selection. Nevertheless, in recent years, new
bioprocesses have been also designed by recombinant DNA
technology approaches, that open up new opportunities for
the construction of more robust and versatile microbial
cell factories (MCF) for the production of steroids à la
carte.
Regardless of the aforementioned approaches, steroid
synthesis bioprocesses can be classified into three groups:
(i) bioprocesses for production of steroidal intermediates
from natural sterols, (ii) bioprocesses for modification and/or
functionalization of steroidal molecules, (iii) de novo biosynthesis
of steroids (Figure 2). A more detailed description of these
bioprocesses is presented below, highlighting the most relevant
achievements in the last decades, as well as outlining the trends
and perspectives of research into this field. In no case, this
review intends to carry out a comprehensive analysis of all the
publications, patents and microbial strains described so far.
CURRENT ACHIEVEMENTS OF STEROID
BIOTECHNOLOGY
Microbial Production of Steroidal
Intermediates From Sterols
Natural sapogenins such as diosgenin have been used as basic
precursors in the steroid chemistry for decades (Figure 1;
Herráiz, 2017). For example, 16-dehydropregnenolone acetate
derived from diosgenin can be converted to valuable steroids
by chemical synthesis processes (Hanson, 2005; Laveaga, 2005).
Diosgenin can be also transformed into steroidal intermediates
with therapeutic activities by microbial biotransformation
(Wang et al., 2007; Wang F. Q. et al., 2009; Wang W.
et al., 2009). Nevertheless, the utilization of sapogenins as
feedstock has been significantly reduced since it presents several
drawbacks: high costs, multiple steps, low yields, and wild
plant resources depletion (Tong and Dong, 2009; Wang et al.,
2011). Therefore, sapogenins have been progressively replaced
by several natural sterols (e.g., phytosterols, cholesterol) that can
also be biotransformed into steroidal derivatives with properties
similar to certain sex hormones (Figure 1). These steroidal
derivatives, which are actually intermediates or byproducts of
the sterol catabolic pathway (e.g., AD) (see below), are currently
used as key precursors (synthons) for the chemical synthesis of
steroid-based drugs such as corticosteroids, mineralocorticoids
and oral contraceptives. Several types of phytosterols (e.g.,
soybean, pine, paper industry wastes) are used generally as
industrial feedstock instead of cholesterol (obtained from animal
fats and oils), due to the exhaustive quality controls required for
the use of any type of animal basic precursor (Fernandes et al.,
2003; Malaviya and Gomes, 2008).
In general, actinobacteria producing mycolic acids such
as those belonging to the genera Gordonia, Mycobacterium,
Nocardia, and Rhodococcus, are able to metabolize cholesterol
and other natural sterols (Donova, 2010; García et al., 2012; Galán
et al., 2017a). In last decades numerous members of these genera
have been isolated from different natural sources (e.g., soil) and
subsequently optimized by conventional mutagenesis to select
bacterial strains that produce steroidal intermediates of interest.
For example, the C-19 steroids (e.g., AD, ADD, 9OH-AD, and
TS), the C-22 steroids (e.g., 4-HBC, 1,4-HBC, 9OH-4-HBC) and
the sitolactone intermediate are currently produced from sterols
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FIGURE 1 | Chemical structures of relevant steroidal compounds containing the gonane tetracyclic skeleton. Structures of basic precursors, key intermediates
(synthons) and active pharmaceutical ingredients (APIs) are shown. AD, 4-androstene-3,17-dione; ADD, 1,4-androstadiene-3,17-dione; 9OH-AD,
9α-hydroxy-4-androstene-3,17-dione; 4-HBC, 22-hydroxy-23,24-bisnorchol-4-ene-3-one; 1,4-HBC, 22-hydroxy-23,24-bisnorchol-1,4-diene-3-one; 9OH-4-HBC,
9,22-dihydroxy-23,24-bisnorchol-4-ene-3-one; 11OH-AD, 11α-hydroxy-4-androstene-3,17-dione; DHEA, 3β-hydroxy-5-androstene-7-one, dehydroepiandrosterone;
TS, testosterone.
by microbial bioconversion (Figure 1). Interestingly, only strains
of the genusMycobacterium are used for production purposes at
an industrial scale (Marsheck et al., 1972; Imada and Takahashi,
1980; Knight and Wovcha, 1981; Liu and Meng, 1981; Liu et al.,
1994; Lo et al., 2002; Donova et al., 2005a,b; Wei et al., 2010a;
Supplementary Table 1). New steroid-producing strains have also
been rationally designed by metabolic engineering approaches
in recent years (Table 1). Since certain C-19 steroids (e.g., AD,
ADD, 9OH-AD) have been postulated as intermediates of the
(chole)sterol catabolic pathway in actinobacteria (García et al.,
2012; Galán et al., 2017a), redirecting metabolic fluxes toward
their accumulation can be addressed by gene deletion and/or
overexpression (Figure 3). For instance, the mutant strains of
Mycobacterium smegmatis named MS6039 (1MSMEG_6039,
1kshB1) and MS6039-5941 (1MSMEG_6039 1MSMEG_5941,
1kshB1 1kstD1) mainly produced ADD and AD from sterols,
respectively (Galán et al., 2017b). Several multiple-gene-deletion
mutants of M. neoaurum ATCC 25795 were developed to
produce 9OH-AD or C-22 derivatives from sterols (Yao et al.,
2014; Xu et al., 2016). Furthermore, the overepression of the
kshA gene in the 9OH-AD-producing mutant of M. neoaurum
contributed greatly to improve the process selectivity by reducing
the accumulation of undesirable byproducts (e.g., AD) that
impair downstream purification processes (Yao et al., 2014).
Wei et al. (2010b) also engineered an AD-producing mutant by
deleting the kstD gene ofM. neoaurumNwlB-01, which had been
previously isolated from soil samples and selected because of its
ability to accumulate mixtures of AD/ADD from phytosterols.
Alternatively, Wei et al. (2014) improved the production of ADD
in the strain NwlB-01 by the overexpression of various kstD genes
from different sources. Similarly, Yuan et al. (2015) constructed a
9OH-AD-producing strain by overexpressing the kshA and kshB
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FIGURE 2 | Classification of the microbial bioprocesses for steroid synthesis described to date: (i) production of steroidal intermediates from natural sterols (e.g.,
bioconversion of phytosterols into ADD); (ii) functionalization of steroidal molecules (e.g., bioconversion of AD into ADD); (iii) de novo biosynthesis of steroids (e.g.,
biosynthesis of hydrocortisone from non-steroidal substrates). Several microbial strains, isolated from natural sources and improved by conventional mutagenesis or
designed by using recombinant DNA technologies, are used as microbial cell factories (MCF) to produce key steroidal intermediates (synthons). The resulting synthons
are subsequently modified by chemical steps or additional bioconversion processes to synthetize final steroidal active pharmaceutical ingredients (APIs).
genes from M. smegmatis mc2155 and Gordonia neofelifaecis,
respectively, in the strain Mycobacterium sp. NRRL B-3805
lacking 9α-hydroxylase activity. Finally, Fernández-Cabezón
et al. (2017a) overexpressed two 17β-HSD genes from different
sources in M. smegmatis MS6039-59410 with the objective of
producing testosterone from sterols in a single fermentation
step.
Other authors have attempted to construct mutant strains
producing steroidal intermediates from sterols in species of the
genus Rhodococcus. However, the presence of multiple steroid
catabolic pathways apparently convergent and the existence of
basal levels of certain isoenzymes (e.g., KstD, KshA, or KshB)
have hindered the development of stable producers in these
species (van der Geize et al., 2000, 2001, 2002a,b, 2008; Petrusma
et al., 2011; Fernández de las Heras et al., 2012; Liu et al.,
2016; Guevara et al., 2017a,b). In certain members of the genus
Mycobacterium such as M. smegmatis, M. tuberculosis or M.
neoaurum, the deletion of a single key gene (kshA, kshB, or kstD)
appears to be sufficient to prevent an efficient mineralization
of sterols (Brzostek et al., 2005; Andor et al., 2006; Capyk
et al., 2009; Brzezinska et al., 2013; Yao et al., 2014; Galán
et al., 2017b). In contrast, the deletion of five kshA genes was
needed to construct a mutant strain of Rhodococcus rhodochrous
DSM43269 incapable of mineralizing sterols (Petrusma et al.,
2011). Similarly, two kstD genes were deleted into R. ruber str.
Chol-4 to avoid cholesterol mineralization (Fernández de las
Heras et al., 2012). So far, only Yeh et al. (2014) were able
to design an ADD-producing strain of Rhodococcus equi by
deleting only one kshB gene. Moreover, the equivalent mutants
of the genus Mycobacterium and Rhodococcus accumulate
different types and/or amounts of steroidal intermediates from
sterols. For instance, AD/ADD-producing mycobacterial strains
accumulate small amounts of 4-HBC/1,4-HBC alcohols, whereas
the respective mutants of Rhodococcus accumulate notable
amounts of their acid derivatives 3-oxo-23,24-bisnorchol-4-en-
22-oic acid (4-BNC) and 3-oxo-23,24-bisnorchol-1,4-dien-22-oic
acid (1,4-BNC) (Marsheck et al., 1972; Wilbrink et al., 2011;
Yeh et al., 2014; Xu et al., 2016; Galán et al., 2017b). For
example, Wilbrink et al. (2011) constructed a mutant strain of R.
rhodochrousDSM 43269 (strain RG32) devoid of 9α-hydroxylase
activity, which accumulated mostly 1,4-BNC and only small
amounts of ADD from sterols.
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TABLE 1 | Microbial production of steroidal intermediates from natural sterols by recombinant DNA technology approaches.
Parental Strain Main product Genetic manipulations
M. neoaurum NwlB-01 ADD Overexpression of an endogenous kstD gene or a heterologous kstD gene derived
from the bacterium Arthrobacter simplex (Wei et al., 2010b, 2014)
R. equi USA-18 ADD Deletion of the kshB1 gene (Yeh et al., 2014)
M. neoaurum ATCC 25795 AD/ADD Deletion of the kshA1 and kshA2 genes (strain named NwIB-XII) (Xu et al., 2016)
M. smegmatis mc2155 (1) AD
(2) ADD
(1) Deletion of the kshB1 and kstD1 genes (strain named MS6039-5941); (2) Deletion
of the kshB1 gene (strain named MS6039) (Galán et al., 2017b)
M. neoaurum ATCC 25795 9OH-AD Multiple deletion of several kstD genes and overexpression of an endogenous kshA
gene (Yao et al., 2014)
Mycobacterium sp. NRRL
B-3805
9OH-AD Overexpression of the kshA and kshB genes of M. smegmatis mc2155 and G.
neofelifaecis NRRL B-59395, respectively (Yuan et al., 2015)
R. rhodochrous DSM43269 1,4-HBC Multiple deletion of all the kshA genes (1ksA12345) (Petrusma et al., 2011; Wilbrink
et al., 2011)
M. neoaurum ATCC 25795 (1) 4-HBC
(2) 1,4-HBC
(3) 9OH-4-HBC
(1) Deletion of multiple kshA and kstD genes (1kstD123, 1kshA12) and hsd4A gene;
(2) Deletion of multiple kshA genes (1kshA12) and the hsd4A gene; (3) Deletion of
multiple kstD genes (1kstD123) and the hsd4A gene (Xu et al., 2016)
M. smegmatis MS6039-5941
(Galán et al., 2017b)
TS Overexpression of two genes encoding 17b-HSDs from Comamonas testosteroni
and Choliobolus lunatus (Fernández-Cabezón et al., 2017a)
Several examples of actinobacterial strains designed by Metabolic Engineering approaches for this purpose are shown. Main end products obtained at the bioconversions and no other
by-products are indicated. ADD, 1,4-androstadiene-3,17-dione; AD, 4-androstene-3,17-dione; 9OH-AD, 9α-hydroxy-4-androstene-3,17-dione; TS, 17β-hydroxy-4-androstene-3,17-
dione; testosterone; 1,4-HBC, 22-hydroxy-23,24-bisnorchol-1,4-diene-3-one; 4-HBC, 22-hydroxy-23,24-bisnorchol-4-ene-3-one; 9OH-4-HBC, 9,22-dihydroxy-23,24-bisnorchol-4-
ene-3-one.
The successful implementation of the aforementioned
metabolic engineering approaches would not have been possible
without the numerous studies of catabolic pathways of steroids
developed in various model actinobacteria (e.g., M. smegmatis
mc2155, R. jostiiRHA1,M. tuberculosisH37Rv), the development
of new molecular biology tools for genetic manipulation of these
non-model bacteria and the sequencing and annotation of their
genomes (Kendall et al., 2007, 2010; van der Geize et al., 2007;
Mohn et al., 2012; Uhía et al., 2012; Haußmann et al., 2013; Li
et al., 2014; Bergstrand et al., 2016; Crowe et al., 2017).
Microbial Functionalization of Steroidal
Molecules
The chemical modification of steroidal molecules has attracted
considerable attention in last decades. Baeyer-Villiger oxidations,
hydroxylations, and reduction-oxidation (redox) reactions are
some of the most relevant modifications (functionalizations)
performed on steroidal compounds by chemical synthesis
processes. These and other functionalizations of steroids can
alternatively be performed by biocatalytic procedures. For
example, redox reactions such as oxidations of alcohols,
reductions of carbonyl groups, dehydrogenations of C-C bonds
or hydrogenations of C-C double bonds, can be catalyzed
by specific enzymes. The 11,2-dehydrogenation and the 17β-
reduction of 3-ketosteroids are two examples of enzymatic
redox reactions of relevance for steroid synthesis (Figure 4).
Hydroxylations of steroidal molecules, in which a hydrogen atom
is replaced by a hydroxyl group (e.g., 7α, 9α-, 11α-, 11β-, 16α-,
and 17α-hydroxylation), can also be catalyzed by several families
of hydroxylase enzymes such as multicomponent cytochromes
P450 and monooxygenases (Figure 4). Even the classical Baeyer-
Villiger oxidations, in which an ester/lactone is generated
from a ketone/cyclic ketone (e.g., transformation of ADD into
testolactone, an aromatase inhibitor) (Kołek et al., 2008), can
be catalyzed by enzymes called Baeyer-Villiger monooxygenases
(BVMOs) that use molecular oxygen and NADPH (Figure 4;
Leisch et al., 2011). To perform these chemical functionalizations
on steroidal molecules, several wild-type microorganisms that
possess the steroid-modifying enzymatic activities of interest
are frequently used at an industrial scale (Supplementary Table
2; Zhang et al., 1998; El-Kadi and Mostafa, 2004; Li et al.,
2005, 2017; Reese, 2007; Roglicˇ et al., 2007; Manosroi et al.,
2008; Yildirim et al., 2010; Peart et al., 2011; Bhatti and Khera,
2012; Donova and Egorova, 2012; Prakash and Bajaj, 2017).
Since these bioconversions often exhibit various drawbacks
such as low selectivity and substrate conversion yields, and
may even require the culture of opportunistic pathogenic
microorganisms (e.g., Rhizopus oryzae), it has been proposed
the design of alternative MCFs by using recombinant DNA
technologies in recent years. Several model microorganisms such
as Escherichia coli, Bacillus subtilis, or Saccharomyces cervisiae
have been chosen to heterologously express one or more genes
encoding the proteins involved in the single enzymatic steps
of interest mentioned above (i.e., 9α-hydroxylation and 11,2-
dehydrogenation of 3-ketosteroids) (Figure 4, Table 2; Andor
et al., 2006; Arnell et al., 2007; Li et al., 2007; Petrusma et al.,
2009; Zhang W. et al., 2013; Zhang et al., 2016; Shao et al., 2017).
Non-conventional yeasts and bacteria (e.g., Schizosaccharomyces
pombe, Pseudomonas putida) have been also used for this purpose
(Ruijssenaars et al., 2007; Hakki et al., 2008; Petricˇ et al., 2010
Table 2). To our knowledge, none of the bioprocesses designed
by using recombinant DNA technologies has been industrially
implemented due to the low achieved substrate conversions
that seem to be the consequence of an inefficient transport
of steroids. For this reason, the rational genetic improvement
of microorganisms capable of efficiently transporting and
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modifying steroids may be a challenging approach to follow.
Zhang W. et al. (2013) increased successfully the 3-ketosteroid-
11-dehydrogenase activity of an Arthrobacter simplex strain by
genomic integration of multiple copies of the endogenous ksdD
gene under the control of a constitutive promoter, reaching
with the recombinant strain a conversion yield of substrate
32.9% higher than that of wild-type strain. Similarly, Kiss et al.
(2015) increased the endogenous 15β-hydroxylase activity in B.
megaterium by overexpressing the cytochrome CYP106A2.
Alternatively, several authors have developed high-yield
bioconversions of steroids based on in vitro enzymatic processes
that use recombinant proteins purified or obtained as cleared
cell lysate and that frequently incorporate a couple enzyme to
recycle the cofactor consumed in the reaction (i.e., NAD(P)/H)
(Fogal et al., 2013; Hoebenreich et al., 2017). None of these
bioprocesses has been implemented industrially to date due to
the high production cost of active recombinant enzymes.
De novo Biosynthesis of Steroids in Yeasts
Several microbial bioprocesses designed by synthetic biology and
system biology approaches have been successfully implemented
for the industrial production of high-added value compounds
(Lee et al., 2016; Nielsen and Keasling, 2016; Silber et al.,
2016). However, steroid industry has hardly explored this path,
and there are only two examples that highlight the potential
of these disciplines. De novo biosynthesis of progesterone and
hydrocortisone from simple carbon sources (e.g., galactose,
ethanol) was successfully achieved in recombinant strains of
Saccharomyces cerevisiae, by engineering the endogenous sterol
biosynthesis pathway to generate a cholesterol-like molecule that
served as a precursor to a multi-enzymatic heterologous route
mimicking human steroid biosynthesis (Duport et al., 1998;
Szczebara et al., 2003).
CURRENT CHALLENGES OF STEROID
BIOTECHNOLOGY
Constructing a Second Generation of
Mycobacterial Strains
The economic feasibility of certain industrial bioprocesses
for steroid production is limited by low sterol conversion
yields and low product selectivity achieved with the
currently available Mycobacterium strains. Consequently,
the construction of a second generation of MCFs with
improved properties is one of the most relevant short-term
challenges for the production of steroidal intermediates
from sterols. By implementing the knowledge related to
the bacterial steroid catabolism acquired in recent years
and a combination of empirical methodologies proposed
below, new more robust industrial bioprocesses may be
designed.
In last years the genome sequencing and annotation of
several industrial mycobacterial strains obtained by traditional
approaches has been reported (e.g., Mycobacterium sp. NRRL
B-3805, Mycobacterium sp. NRRL B-3683, Mycobacterium sp.
VKM Ac-1815D) (Bragin et al., 2013; Shtratnikova et al.,
2014, 2015; Rodríguez-García et al., 2016). The mutations
present in these industrial strains have also been determined
with the aim of identifying potential genetic targets for a
rational design of new highly-producer MCFs. Complementary
approaches to conventional mutagenesis such as the Adaptive
Laboratory Evolution (ALE) can be applied for this same
purpose. The ALE methodology has already been implemented
to optimize numerous bioprocesses over the last 25 years
(Dragosits and Mattanovich, 2013). Taking into account that
overproduction of compounds and high stress tolerances are
determined by interaction of multiple parameters/factors, that
are not always known and predictable and therefore cannot
be easily addressed through rational approaches, the ALE
methodology based on long-term adaptation of microbial
strains can be an interesting alternative. By progressively
increasing the sterol concentration of the medium in a
chemostat or in several consecutive batch cultures, ALE
evolved strains that efficiently biotransform sterols into steroidal
intermediates could be selected (Mondaca et al., 2017). In
addition, ALE methodology could be combined with reverse
engineering strategies, which seek to “rationalize” the selected
phenotypes by identifying the mutations present in the evolved
strains and improve them, if possible, in new rounds of
evolution.
A better understanding of the steroid catabolic complexity
may be also key to optimizing several current industrial
bioprocesses in actinobacteria. The partial degradation of
products described in many mycobacterial strains could be
avoided through the elimination of undesirable enzymatic
activities via rational gene deletion. Yao et al. (2014)
demonstrated that two residual enzymatic activities KstD
(KstD2 and KstD3) present in the mutant MutMN−KSTD1
(1kstD1) of M. neoaurum ATCC 25795 markedly decreased
the conversion yield of 9OH-AD from sterols. Interestingly,
KstD2 and KstD3 enzymes are encoded by genes located
in a second steroid gene cluster that is homologous to the
C-19+ cluster recently described in M. smegmatis, which has
apparently evolved independently from the upper cholesterol
kstR-regulon and appears to be necessary for the efficient
metabolization of C-19 steroids in this bacterium (i.e., AD, ADD,
9OH-AD) (Fernández-Cabezón et al., 2017b). Certain industrial
mycobacterial strains such as M. neoaurum VKM Ac-1815D
and Mycobacterium sp. NRRL B-3805 do not have the C-19+
gene cluster. In fact, a genomic deletion of this cluster is found
when their genomes are compared to the genome of the close
phylogenetic strain M. neoaurum DSM 44074 (ATCC 25795).
Therefore, the deletion of the C-19+ gene cluster or of certain
genes located therein (e.g., kstD, kshA, kshB), may increase the
bioconversion yields of those producer strains derived from M.
smegmatis, M. neoaurum or other mycobacteria carrying the
C-19+ cluster. On the other hand, the identification of enzymes
involved in each of the steps of sterol catabolism may be useful
for the construction of new strains producing new steroidal
intermediates of industrial interest (e.g., 4-HBC, 1,4-HBC,
9-OH-4-HBC) (Xu et al., 2016), as well as in the determination
of limiting enzymatic steps leading to low conversion yields
and accumulation of undesirable by-products. For example, a
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FIGURE 3 | Scheme of the rational construction of mycobacterial strains producing steroidal intermediates from natural sterols by metabolic engineering approaches.
Based on the knowledge of the catabolic pathway of sterols in actinobacteria, the redirection of metabolic flux toward the accumulation/synthesis of C-19 (red) or
C-22 (gray) steroidal intermediates can be addressed via single/multiple gene deletions. The metabolic flux can be also redirected to the synthesis of new steroidal
compounds by incorporating heterologous enzymatic activities (pink) (e.g., 17β-hydroxysteroid dehydrogenase, 17β-HSD). kstD, 3-ketosteroid-11-dehydrogenase;
ksh, 3-ketosteroid-9α-hydroxylase; hsd4A, hydroxysteroid dehydrogenase. Abbreviations of metabolites: ADD, 1,4-androstadiene-3,17-dione; AD,
4-androstene-3,17-dione; 9OH-AD, 9α-hydroxy-4-androstene-3,17-dione; TS, 17β-hydroxy-4-androstene-3,17-dione; testosterone; 1,4-HBC,
22-hydroxy-23,24-bisnorchol-1,4-diene-3-one; 4-HBC, 22-hydroxy-23,24-bisnorchol-4-ene-3-one; 9OH-4-HBC, 9,22-dihydroxy- 23,24-bisnorchol-4-en-3-one.
deep understanding of the enzymatic steps involved into the
sterol side-chain degradation could be useful for the design of
new AD/ADD-producing strains that do not accumulate the
intermediates 4-HBC/1,4-HBC. In order to further understand
the regulatory mechanisms of sterol catabolism and steroid
production, several transcriptomic and proteomic studies
have been also done in recent years, increasingly focused
on higher-producer strains (Liu et al., 2016a,b; Xiong et al.,
2017a,b).
The characterization of the C-19+ gene cluster above
mentioned, as well as of other steroid degradation gene
clusters in bacteria, has allowed to identify multiple steroid-
modifying isoenzymes with different catalytic properties (e.g.,
substrate specificity, cellular localization) (Knol et al., 2008;
Petrusma et al., 2011, 2012; Penfield et al., 2014; Guevara
et al., 2017a,b; Wang et al., 2017), that should be considered
to design more efficient industrial bioprocesses. For example,
the selective production of ADD from sterols in a single
fermentation step remains a challenge at an industrial scale.
To date, all available mycobacterial strains accumulate mixtures
AD/ADD that hamper the subsequent purification processes
(Marsheck et al., 1972; Wei et al., 2010b; Galán et al., 2017b).
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FIGURE 4 | Microbial functionalization of steroidal molecules of industrial relevance. (A) 11-Dehydrogenation of 3-ketosteroids: conversion of cortisone into
prednisone. (B) 9α-Hydroxylation of 3-ketosteroids: conversion of progesterone into 9α-hydroxy-progesterone. (C) 11α-Hydroxylation of 3-ketosteroids: conversion
de AD into 11α-hydroxy-AD. (D) Baeyer-Villiger oxidation: conversion of ADD into testolactone. KstD, 3-ketosteroid-11-dehydrogenase, KSH,
3-ketosteroid-9α-hydroxylase, P450, 11α-hydroxylase, cytochrome P450, BMVO, Baeyer-Villiger monooxygenase.
Several hypotheses have been raised about the impossibility
of achieving bioconversions close to 100%: (i) existence of
certain enzymatic activities 1-en reductase that catalyze the
reverse reaction (Goren et al., 1983; Egorova et al., 2002);
(ii) phenomena of inhibition and/or toxicity because of the
ADD accumulation (Smith et al., 1993); (iii) insufficient levels
of enzymatic activity KstD (Wei et al., 2014). On the basis
of this latter hypothesis, several authors have overexpressed
endogenous or heterologous kstD genes (involved into the
sterol catabolism) in ADD-producing strains that have led to
remarkable improvements in bioconversion selectivity but still
insufficient (Wei et al., 2010b, 2014). Surprisingly, the utilization
of alternative kstD genes involved into different steroid catabolic
pathways or even a combination of kstD genes have not been
explored yet. For instance, the simultaneous overexpression of
the kstD1 (MSMEG_5941) and kstD2 (MSMEG_2869) genes
from M. smegmatis involved into the cholesterol and C-
19 steroids catabolism, respectively, could be investigated in
ADD-producing strains with the aim of favoring the 11,2-
dehydrogenation reactions in different steps (on different
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TABLE 2 | Microbial functionalization of steroidal molecules by recombinant DNA technology approaches.
Substrate Main product Microorganism Genetic manipulation
AD ADD B. subtilis WB600 Overexpression of the ksdD gene from A. simplex AS1.94 (Li et al., 2007)
AD ADD B. subtilis 168 Overexpression of the ksdD gene from M. neoaurum JC-12 (Zhang W. et al., 2013)
AD ADD B. subtilis 168 Hyperproduction of the KsdD protein from M. neoaurum JC-12 (gene codon
optimization). Overexpression of the katA gene from Bacillus pumilus ML 413
encoding a catalase to reduce the endogenous levels of H2O2 (Shao et al., 2017)
AD ADD R. ruber str. Chol-4 Multiple deletion of several kshA genes (1kshA123) or single deletion of kshB gene
(1kshB) (Guevara et al., 2017b)
Cortisone acetate Prednisone acetate A. simplex 156 Overexpression of the endogenous ksdD gene by integrating multiple gene copies
under the control of a constitutive promoter (Zhang H. et al., 2013)
AD 9OH-AD E. coli BL21 Overexpression of the kshA1 gene from M. smegmatis mc2155 (Andor et al., 2006)
AD 9OH-AD E. coli BL21 Overexpression of the kshA and kshB genes from R. rhodochrous DSM 43269
(Petrusma et al., 2009)
AD 9OH-AD B. subtilis 168 Overexpression of the kshA gene from M. neoaurum JC-12 and the endogenous gdh
gene encoding a 1-dehydrogenase glucose to regenerate NADH (Zhang et al., 2016)
AD 9OH-AD R. ruber str. Chol-4 Multiple deletion of several kstD genes (1kstD123) (Fernández de las Heras et al.,
2012)
Progesterone 9α-Hydroxy-progesterone E. coli BL21 Overexpression of the kshA1 gene from M smegmatis mc2155 (Arnell et al., 2007)
AD Testosterone M. smegmatis mc2155 Overexpression of a gene encoding a 17b-HSDs from Comamonas testosteroni or
Cochliobolus lunatus (Fernández-Cabezón et al., 2017a)
DHEA 7α-Hydroxy-DHEA S. cerevisiae Overexpression of the gene encoding cytochrome CYP7B (Vico et al., 2002)
Progesterone 11α-Hydroxy-progesterone Schizosaccharomyces
pombe 1445
Hyperproduction of 11 α-hydroxylase from R. oryzae (co-expression of all
constituents: cytochrome CYP509C12 and NAD(P)H reductase) (Petricˇ et al., 2010)
11-Deoxycortisol Hydrocortisone S. pombe Hyperproduction of the human 11β-hydroxylase (co-expression of all constituents:
cytochrome CYP11B1, adrenoxin and adrenoxin reductase) (Hakki et al., 2008)
11-Deoxycorticosterone 15β-Hydroxy-
deoxycorticosterone
E. coli Hyperproduction of 15β-hydroxylase from B. megaterium (coexpression of all
constituents: cytochrome P450, adrenoxin and adrenoxin reductase) (Hannemann
et al., 2006)
Testosterone 15β-Hydroxy-testosterone P. putida S12 Overexpression of the gene encoding cytochrome CYP106A2 from B. megaterium
(Ruijssenaars et al., 2007)
Cyproterone acetate 15β- Hydroxy-cyproterone
acetate
B. megaterium ATCC
13368
Overexpression of the endogenous gene encoding cytochrome CYP106A2
(15β-hydroxylase) (Kiss et al., 2015)
Progesterone 17α-Hydroxy-progesterone Pichia pastoris GS115 Overexpression of the gene encoding human cytochrome P45017 (17α-hydroxylase)
(Kolar et al., 2007)
(1) DHEA
(2) PREG
(3) C1
(1) AD
(2) PROG
(3) C2
C. glutamicum R31 Overexpression of the 3β-hydroxysteroid dehydrogenase/ isomerase gene
(MSMEG_5228) from M smegmatis mc2155 (García-Fernández et al., 2017)
Several examples of recombinant strains designed to modify stereo- and regio-specifically steroidal molecules of pharmacological interest are shown. Main end products
obtained at the bioconversions and not other by-products identified are indicated. ADD, 1,4-androstadiene-3,17-dione; AD, 4-androstene-3,17-dione; 9OH-AD , 9α-hydroxy-4-
androstene-3,17-dione; DHEA, 3β-hydroxy-5-androstene-7-one; dehydroepiandrosterone; C1, 5-pregnen-16α,17α-epoxy-16β-methyl-3β-ol-20-one; epoxymethylpregnenolone; C2,
4-pregnen-16α,17α-epoxy-16β-methyl-3,20-dione; epoxymethylprogesterone.
substrates) during the sterol bioconversion (Supplementary
Figure 1).
Finally, the construction of new MCFs is necessary for the
direct conversion of sterols into steroidal compounds that are
not part of the steroid catabolism in bacteria (e.g., 11α-OHAD,
11β-OHAD, 17β-OHAD). As mentioned above, most of these
compounds are currently synthesized in a second fermentation
step from C-19 or C-22 steroidal intermediates. The need for
a second fermentation involves further purification steps of
intermediate products and a significant increase in the time
and cost of the overall process. Therefore, the development of
one-step bioprocesses by incorporating new steroid-modifying
enzymatic activities in certain mycobacterial strains may be
a convenient approach. For example, the overexpression of
several heterologous genes encoding 11α-hydroxylases in the
AD-producing mutant M. smegmatis MS6039-5941 have been
already proposed to synthesize 11α-OHAD from (phyto)sterols
in a one-step fermentation (Ríos et al., 2017). However,
given that most of these enzymatic reactions are catalyzed
by membrane-associated multicomponent cytochromes P450
which are very abundant in their native microorganisms
(e.g., certain species of fungi have among several tens to
a hundred of cytochromes P450), significant efforts will
be required to identify the genes encoding the enzymatic
activities of interest, as well as to achieve an adequate
production of active enzyme that allows redirecting fully (or
mostly) the metabolic flow toward the formation of steroidal
product.
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MICROBIAL FUNCTIONALIZATION OF
STEROIDS
The challenges proposed above are based on the utilization of
mycobacterial species as MCFs. However, it is likely that the
biosynthesis of a broad portfolio of steroids cannot be achieved
by using a single microbial chassis as MCF. Therefore, the
identification of alternative microbial chassis, i.e., alternative
microorganisms with desirable properties (e.g., efficient steroid
transport, high stress tolerance, non-pathogenicity, absence of
undesired steroid-modifying enzymatic activities, availability
of multiple genetic modification tools), must be investigated.
For example, the utilization of the well-known industrial
actinobacteria Corynebacterium glutamicum has been recently
applied for designing new functionalization bioprocesses of
steroids (García-Fernández et al., 2017).
On the other hand, the identification of novel steroid-
modifying enzymes is also required for the design of new
bioprocesses. To do this, several approaches such as the
exploration of alternative ecological niches (e.g., marine, anoxic
and thermopile environments) by means of metagenomic
approaches, the annotation of genomes available in database,
the development of new proteins by protein engineering
and the implementation of high-throughput assays for strain
screening can be applied. For example, Ribeiro et al. (2017)
have investigated the identification of thermostable enzymes
for developing in vitro bioconversions of steroids, since
thermostability can increase not only the enzyme half-life but also
the solubility of steroids notably improving reaction yields.
De novo Biosynthesis of Steroids in
Actinobacteria
Most of the limitations observed in current industrial
bioprocesses are directly related to the intrinsic properties
of steroidal molecules (e.g., low solubility in aqueous media,
high cell toxicity). With the aim of overcoming these limitations,
different technological approaches such as micronization or
emulsification with surfactants of steroidal substrates, utilization
FIGURE 5 | Current challenges of steroid biotechnology. New microbial cell factories are needed to design new industrial bioprocesses for the production of steroids
à la carte, i.e., more robust one-step biotechnological processes with higher substrate conversion yields and product selectivity. Using multiple currently available
methodologies, at least the following challenges should be addressed: (i) construction of a second generation of mycobacterial strains for the production of steroidal
intermediates from sterols; (ii) identification of new microbial chassis and steroid-modifying enzymatic activities for the functionalization of steroidal molecules; (iii) de
novo biosynthesis of steroids from non-steroidal substrates in mycobacteria.
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of solvent organics in two-phase systems, cell immobilization
and development of in continuous or in situ production systems
have been investigated in recent years (de Carvalho et al., 2004;
Donova et al., 2007; Egorova et al., 2009; Lam, 2010; Marques
et al., 2010; Donova and Egorova, 2012; Galán et al., 2017a).
Alternatively, the development of MCFs capable of de
novo synthesizing steroids from conventional feedstock such as
glucose has been proposed. In this sense, it was mentioned
previously that the de novo biosynthesis of progesterone and
hydrocortisone was successfully achieved in recombinant strains
of S. cerevisiae (Duport et al., 1998; Szczebara et al., 2003).
Similarly, de novo biosynthesis of steroids in mycobacteria
might be also achieved (Supplementary Figure 2). Briefly,
taking account that steroids are part of the isoprenoid family
that are synthesized in all organisms through a modular
synthesis pattern, it is possible to channel the metabolic
flux of the universal isoprenoid precursors (i.e., isopentenyl
pyrophosphate, IPP; dimethylallyl pyrophosphate, DMAPP)
toward the synthesis of squalene through a limited number
of heterologous enzymatic steps and, from this compound,
to generate by cyclization the steroidal molecule lanosterol.
Thus, it is possible to assemble an artificial biosynthetic route
of sterols with a partially-interrupted cholesterol catabolic
pathway to synthesize steroidal intermediates of interest. The
bioconversion of lanosterol into steroidal intermediates of
interest by Mycobacterium sp. NRRL B-3805 has been already
described (Wang et al., 1995). Nevertheless, for a successful
implementation on an industrial scale of the approaches detailed
here, new genetic tools must be designed. In recent years
significant advances have been made in the development of
genome-editing tools (e.g., recombineering-assisted by CRISPR-
Cas9), which facilitate the construction of microbial strains
for different purposes such as the industrial applications of
White Biotechnology (Pines et al., 2015; Jakocˇiunas et al., 2016).
These tools allow the simultaneous introduction of several
types of genomic modifications, shortening the time of strain
development and avoiding the use of selection markers. At
present, a recombineering system for the genomic modification
of mycobacteria is available (Murphy et al., 2015) and a CRISPR-
Cas9 interference system (CRISPRi) has been successfully
implemented (Choudhary et al., 2015; Rock et al., 2017), which
opens the possibility of designing even more versatile genome
editing systems in mycobacteria (e.g., recombineering assisted
by CRISPR-Cas9). For instance, Yan et al. (2017) have recently
developed a recombineering assisted by CRISPR-Cas12a (Cpf1)
(i.e., a new type of CRISPR-Cas system), that allows an efficient
editing of M. smegmatis genome. Moreover, in the next few
years, additional efforts must be also made to construct promoter
libraries of different strength for fine-tuned gene expression in
mycobacteria (Kanno et al., 2016), as well as the engineering of
regulatory circuits for an optimal control of the heterologous
gene expression (Bradley et al., 2016).
CONCLUDING REMARKS
The biotechnological production of steroids as other industrial
bioprocesses, such as the production of amino acids or
antibiotics, has been traditionally based on the isolation of
microorganisms of interest and their subsequent improvement
through physicochemical mutagenesis and selection. Although
in recent years the optimization of several bioprocesses has been
addressed through recombinant DNA technology approaches,
these techniques have not been hardly applied for steroid
synthesis (Lee et al., 2016; Nielsen and Keasling, 2016; Silber
et al., 2016). This fact could be in part explained by the intrinsic
difficulties associated with the utilization of steroids (e.g.,
low solubility in aqueous media, high cell toxicity) and the
difficult genetic manipulation and bad reputation of the MCFs
commonly used in these bioprocesses (i.e., mycobacterial
species). Nevertheless, this trend is changing as we have showed
in this review highlighting the most relevant research carried
out on steroid biotechnology based on recombinant DNA
technologies. In our opinion, the main challenge to become
competitive with the current industrial chemical processes
is to design more robust bioprocesses with higher substrate
conversion yields and product selectivity. An additional
challenge will be to offer a new portfolio of steroids with the
ultimate goal of producing steroids à la carte. To achieve all these
challenges, it will be necessary to construct new MCFs based on
the implementation of Synthetic Biology and Systems Biology
approaches (Figure 5). The long road that must be undertaken
to design bio-sustainable processes such as those proposed here
is justified by the growing demand for steroidal pharmaceuticals
and the commitment increasingly needed with the
environment.
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